Clinical Study

Ea4181- A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab And High Dose Cytarabine (Br/Cr) 2.) Bendamustine, Rituximab, High Dose Cytarabine And Acalabrutinib (Br/Cr-A), And 3.) Bendamustine, Rituximab And Acalabrutinib (Br-A) In Pat

Posted Date: Mar 11, 2020

  • Investigator: Tahir Latif
  • Specialties: Cancer, Lymphoma, Oncology
  • Type of Study: Observational/Survey

This is a study for untreated mantle cell lymphoma patients. The primary objective of this study is to compare the CR/Peripheral blood MRD negative rate between the 3 arms of the study.


To Be Eligible: Patients Must Be Age = 18 Years And = 70 Years, Ecog 0-2, Untreated Histologically Confirmed Mantle Cell Lymphoma, No History Of Hypersensitivity To Study Drugs/Components, No Active Infections Or Medical Disorders That May Affect Treatment



For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.